Schalken JA - Search Results

1

Liquid biopsy in bladder cancer: State of the art and future perspectives.

Crocetto F, Barone B, Ferro M, Busetto GM, La Civita E, Buonerba C, Di Lorenzo G, Terracciano D, Schalken JA. Crocetto F, et al. Among authors: schalken ja. Crit Rev Oncol Hematol. 2022 Feb;170:103577. doi: 10.1016/j.critrevonc.2022.103577. Epub 2022 Jan 5. Crit Rev Oncol Hematol. 2022. PMID: 34999017 Review.

2

Critical review of the models to study the biologic progression of bladder cancer.

Schalken JA, van Moorselaar RJ, Bringuier PP, Debruyne FM. Schalken JA, et al. Semin Surg Oncol. 1992 Sep-Oct;8(5):274-8. doi: 10.1002/ssu.2980080505. Semin Surg Oncol. 1992. PMID: 1462097 Review.

3

Molecular prognostic factors in bladder cancer.

Vet JA, Debruyne FM, Schalken JA. Vet JA, et al. Among authors: schalken ja. World J Urol. 1994;12(2):84-8. doi: 10.1007/BF00184242. World J Urol. 1994. PMID: 7916239 Review.

4

Molecular prognostic factors in bladder cancer.

Schalken JA. Schalken JA. Eur Urol. 1998;33 Suppl 4:13-4. doi: 10.1159/000052254. Eur Urol. 1998. PMID: 9615200 Review. No abstract available.

5

Presence of carcinoma in situ and high 2C-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high-risk Quanticyt.

van Rhijn BW, van der Poel HG, Boon ME, Debruyne FM, Schalken JA, Witjes JA. van Rhijn BW, et al. Among authors: schalken ja. Urology. 2000 Mar;55(3):363-7. doi: 10.1016/s0090-4295(99)00460-4. Urology. 2000. PMID: 10699611

6

Consecutive quantitative cytology in bladder cancer.

van der Poel HG, van Rhijn BW, Peelen P, Debruyne FM, Boon ME, Schalken JA. van der Poel HG, et al. Among authors: schalken ja. Urology. 2000 Oct 1;56(4):584-8. doi: 10.1016/s0090-4295(00)00726-3. Urology. 2000. PMID: 11018610

7

Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence.

Vriesema JL, Atsma F, Kiemeney LA, Peelen WP, Witjes JA, Schalken JA. Vriesema JL, et al. Among authors: schalken ja. Urology. 2001 Sep;58(3):367-71. doi: 10.1016/s0090-4295(01)01217-1. Urology. 2001. PMID: 11549482 Clinical Trial.

8

Quantitative cytology on bladder wash versus voided urine: a comparison of results.

Moonen PM, Peelen P, Kiemeney LA, Boon ME, Schalken JA, Witjes JA. Moonen PM, et al. Among authors: schalken ja. Eur Urol. 2006 Jun;49(6):1044-9; discussion 1049-50. doi: 10.1016/j.eururo.2006.01.029. Epub 2006 Feb 13. Eur Urol. 2006. PMID: 16527392

9

Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.

Hendriks RJ, van Oort IM, Schalken JA. Hendriks RJ, et al. Among authors: schalken ja. Prostate Cancer Prostatic Dis. 2017 Mar;20(1):12-19. doi: 10.1038/pcan.2016.59. Epub 2016 Dec 6. Prostate Cancer Prostatic Dis. 2017. PMID: 27922627 Review.

10

Molecular biomarkers to guide precision medicine in localized prostate cancer.

Smits M, Mehra N, Sedelaar M, Gerritsen W, Schalken JA. Smits M, et al. Among authors: schalken ja. Expert Rev Mol Diagn. 2017 Aug;17(8):791-804. doi: 10.1080/14737159.2017.1345627. Expert Rev Mol Diagn. 2017. PMID: 28635333 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

420 results

Search Page